Horizon Therapeutics Public Limited Company - Ordinary Shares (HZNP): Price and Financial Metrics
Horizon Therapeutics Public Limited Company - Ordinary Shares (HZNP)
Today's Latest Price: $78.72 USD
Updated Jan 15 4:00pm
Add HZNP to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 239 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
HZNP Stock Summary
- The price/operating cash flow metric for Horizon Therapeutics Public Ltd Co is higher than 90.83% of stocks in our set with a positive cash flow.
- Over the past twelve months, HZNP has reported earnings growth of 219.63%, putting it ahead of 93.49% of US stocks in our set.
- Revenue growth over the past 12 months for Horizon Therapeutics Public Ltd Co comes in at 40.76%, a number that bests 87.84% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to Horizon Therapeutics Public Ltd Co, a group of peers worth examining would be TECH, AKAM, WST, MASI, and FTNT.
- HZNP's SEC filings can be seen here. And to visit Horizon Therapeutics Public Ltd Co's official web site, go to www.horizontherapeutics.com.
HZNP Stock Price Chart Interactive Chart >
HZNP Price/Volume Stats
| Current price | $78.72 | 52-week high | $86.67 |
| Prev. close | $78.91 | 52-week low | $23.81 |
| Day low | $76.80 | Volume | 1,414,500 |
| Day high | $79.32 | Avg. volume | 1,622,160 |
| 50-day MA | $72.91 | Dividend yield | N/A |
| 200-day MA | $62.99 | Market Cap | 17.37B |
Horizon Therapeutics Public Limited Company - Ordinary Shares (HZNP) Company Bio
Horizon Pharma plc engages in identifying, developing, acquiring or in-licensing, and commercializing medicines for the treatment of arthritis, pain, inflammatory, and/or orphan diseases in the United States and internationally. The company was founded in 2005 and is based in Dublin, Ireland.
HZNP Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $78.72 | $19.9 | -75% |
We started the process of determining a valid price forecast for Horizon Therapeutics Public Ltd Co with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Horizon Therapeutics Public Ltd Co ranked in the 22th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 74.67%. The most interesting components of our discounted cash flow analysis for Horizon Therapeutics Public Ltd Co ended up being:
- The company's balance sheet shows it gets 95% of its capital from equity, and 5% of its capital from debt. Notably, its equity weight is greater than 68.63% of US equities in the Healthcare sector yielding a positive free cash flow.
- The business' balance sheet suggests that 5% of the company's capital is sourced from debt; this is greater than only 17.7% of the free cash flow producing stocks we're observing.
- Horizon Therapeutics Public Ltd Co's effective tax rate, as measured by taxes paid relative to net income, is at 189 -- greater than 98.86% of US stocks with positive free cash flow.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -75% |
| 1% | -75% |
| 2% | -75% |
| 3% | -75% |
| 4% | -74% |
| 5% | -74% |
Want more companies with a valuation profile/forecast similar to that of Horizon Therapeutics Public Ltd Co? See CNC, IDXX, MDT, BSX, and EHC.
Loading social stream, please wait...